Cochlear implantation for HL patients with GJB2 or SLC26A4 variants before 3.5 years will lead to favorable prognosis, early detection of variants in MT‐RNR1 makes drug‐induced HL preventable (Kochhar et al., 2007; Wang, Ding, et al., 2019; Wu et al., 2015). This evidence concerns the gene SLC26A4 and Hodgkins lymphoma.